The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Adalimumab in Patients with Active Noninfectious Uveitis
Open accessAbstract
BACKGROUND: Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy. We conducted a trial to assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of noninfectious uveitis. METHODS: This multinational phase 3 trial involved adults who had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite having received prednisone treatment for 2 or more weeks. Investigators and patients were unaware of the study-group assignments. Patients were randomly assigned in a 1:1 ratio to receive adalimumab (a loading dose of 80 mg followed by a dose of 40 mg every 2 weeks) or matched placebo. All patients received a mandatory prednisone burst followed by tapering of prednisone over the course of 15 weeks. The primary efficacy end point was the time to treatment failure occurring at or after week 6. Treatment failure was a multicomponent outcome that was based on assessment of new inflammatory lesions, best corrected visual acuity, anterior chamber cell grade, and vitreous haze grade. Nine ranked secondary efficacy end points were assessed, and adverse events were reported. RESULTS: The median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group. Among the 217 patients in the intention-to-treat population, those receiving adalimumab were less likely than those in the placebo group to have treatment failure (hazard ratio, 0.50; 95% confidence interval, 0.36 to 0.70; P<0.001). Outcomes with regard to three secondary end points (change in anterior chamber cell grade, change in vitreous haze grade, and change in best corrected visual acuity) were significantly better in the adalimumab group than in the placebo group. Adverse events and serious adverse events were reported more frequently among patients who received adalimumab (1052.4 vs. 971.7 adverse events and 28.8 vs. 13.6 serious adverse events per 100 person-years). CONCLUSIONS: In our trial, adalimumab was found to be associated with a lower risk of uveitic flare or visual impairment and with more adverse events and serious adverse events than was placebo. (Funded by AbbVie; VISUAL I ClinicalTrials.gov number, NCT01138657 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Gómez‐Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., & Montero, M. D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11137 · Cited by 1,013
Jabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., Louie, J. S., Nussenblatt, R. B., Stiehm, E. R., Tessler, H., Van Gelder, R. N., et al. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00659-0 · Cited by 995
Self-citationGritz, D. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.06.014 · Cited by 847
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684
Degree, duration, and causes of visual loss in uveitis
Durrani, O. M. (2004) · British Journal of Ophthalmology · doi:10.1136/bjo.2003.037226 · Cited by 529
The natural history of uveitis
Nussenblatt, R. B. (1990) · International Ophthalmology · doi:10.1007/bf00163549 · Cited by 514
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis
Santos Lacomba, M., Marcos Martín, C., Gallardo Galera, J. M., Gómez Vidal, M. A., Collantes Estévez, E., Ramírez Chamond, R., & Omar, M. M. (2001) · Ophthalmic Research · doi:10.1159/000055677 · Cited by 296
Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis
Tomkins-Netzer, O., Talat, L., Bar, A., Lula, A., Taylor, S. R. J., Joshi, L., & Lightman, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.007 · Cited by 238
Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients
Díaz-Llopis, M., Salom, D., Garcia-de-Vicuña, C., Cordero-Coma, M., Ortega, G., Ortego, N., Suarez-de-Figueroa, M., Rio-Pardo, M. J., Fernandez-Cid, C., Fonollosa, A., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.018 · Cited by 233
The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU)
Dick, A. D., Forrester, J. V., Liversidge, J., & Cope, A. P. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.06.005 · Cited by 197
Self-citationKempen, J. H., Daniel, E., Gangaputra, S. S., Dreger, K. A., Jabs, D. A., Kaçmaz, R. O., Pujari, S. S., Anzaar, F., Foster, C. S., Helzlsouer, K. J., et al. (2008) · Ophthalmic Epidemiology · doi:10.1080/09286580701585892 · Cited by 131
Self-citationAdalimumab Therapy for Refractory Uveitis: A Pilot Study
Díaz-Llopis, M., Delpech, S. G., Salom, D., et al. (2008) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2007.0104 · Cited by 123
Anti-TNF therapies in the management of acute and chronic uveitis
HALE, S., & Lightman, S. (2006) · Cytokine · doi:10.1016/j.cyto.2005.12.012 · Cited by 93
A three-centre experience with adalimumab for the treatment of non-infectious uveitis
Dobner, B. C., Max, R., Becker, M. D., Heinz, C., Veltrup, I., Heiligenhaus, A., Barisani‐Asenbauer, T., & Mackensen, F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301401 · Cited by 79
Self-citationCordero‐Coma, M., Yilmaz, T., & Önal, S. (2013) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2012.723107 · Cited by 65
Clinical outcome of chronic immunosuppression in patients with non‐infectious uveitis
Menezo, V., Lau, C. H., Comer, M. B., & Lightman, S. (2005) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2005.00904.x · Cited by 29
Management of Sight-Threatening Uveitis
Becker, A., Smith, J., Max, R., & Fiehn, C. (2012) · Drugs · doi:10.2165/00003495-200565040-00005 · Cited by 24
Cited by
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjad108 · Cited by 318
Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis
Bellur, S., McHarg, M., Kongwattananon, W., Vitale, S., Sen, H. N., & Kodati, S. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.5584 · Cited by 34
Aqueous macrophages contribute to conserved CCL2 and CXCL10 gradients in uveitis
Lin, J. B., Pepple, K. L., Concepcion, C., Korshunova, Y., Paley, M. A., Paley, G. L., Laurent, J., Apte, R. S., & Hassman, L. M. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2023.100453 · Cited by 17
Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis
Pichi, F., Smith, S. D., AlAli, S. H., & Neri, P. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.09.008 · Cited by 16
Metadata
- Authors
- Jaffe, G. J., Dick, A. D., Brézin, A. P., Nguyen, Q. D., Thorne, J. E., Kestelyn, P., Barisani-Asenbauer, T., Franco, P., Heiligenhaus, A., Scales, D., Chu, D. S., Camez, A., Kwatra, N. V., Song, A. P., Kron, M., Tari, S., & Suhler, E. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-09-08
- Volume
- 375
- Issue
- 10
- Pages
- 932-943
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2517470674
- Cited by
- 674
- References
- 19
- FWCI
- 56.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.